FVII-CTP: Factor VIIa

Factor VIIa is indicated for:

• treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia
• prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia
• treatment of bleeding episodes in patients with congenital FVII deficiency
• prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency

The estimated market for Factor VIIa is $1.3 billion.